Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Recurrence 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 27fludarabine 19Dexamethasone 18pembrolizumab 12Rituximab 12Etoposide 11venetoclax 10pomalidomide 9Gemcitabine 9Lenalidomide 8fludarabine phosphate 7daratumumab 7Bortezomib 7glofitamab 6carfilzomib 6Vincristine 6obinutuzumab 5Temozolomide 5Prednisone 5Nivolumab 5Immunotherapy, Adoptive 5Doxorubicin 5Cytarabine 5Cisplatin 5Calcium Dobesilate 5selinexor 4cemiplimab 4Carboplatin 4Azacitidine 4zanubrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × 18-O-demethylcervinomycin A2 × 90 days × Clear all
NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
295 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT03848286 2026-05-05

KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Completed
153 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡